The high sensitivity of KRAS/GNAS mutations in conjunction with specificity regarding IPMNs (intraductal papillary mucinous neoplasms) and mucinous PCs (pancreatic cysts) respectively is noticed during NGS strategy regarding PCF contrasting Sanger sequencing [108]. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.